{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:06:57Z","timestamp":1793765217475,"version":"4.6.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>The natural history of lung function in patients with bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant is poorly characterized. Understanding the trajectory of lung function is necessary for prompt clinical recognition and treatment and also for the rational design of prospective studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe the longitudinal trajectory of lung function parameters, including FEV1, in patients with BOS after hematopoietic cell transplant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Subjects with BOS defined by National Institutes of Health consensus guidelines criteria from a recent multicenter prospective trial of combination treatment with fluticasone, azithromycin and montelukast and a retrospective cohort from Fred Hutchinson Cancer Research Center were included. Longitudinal change in FEV1 for each patient was calculated on the basis of available pulmonary function tests in three periods: pre-BOS, from BOS diagnosis to 6 months, and 6\u201318 months after diagnosis. The effect of treatment on FEV1 trajectory was analyzed by univariate and multivariate linear regression. The Kaplan-Meier method was used to estimate survival.<\/jats:p>\n                    <jats:p>Measurements and Main Results: The FEV1 percent predicted value at diagnosis was 46% (interquartile range, 35\u201357%) for trial participants and 53% (interquartile range, 41\u201364%) for the retrospective cohort. There was a concomitant mild reduction in FVC, as well as a marked reduction in forced expiratory flow, midexpiratory phase, at diagnosis. While there was individual heterogeneity, the overall FEV1 trajectory was characterized by a marked decline within 6 months prior to BOS diagnosis, followed by stability of FEV1 early after diagnosis and a slow rate of decline beyond 6 months. The effect of the trial medications on FEV1 trajectory after BOS diagnosis was a mean rate of change of 0.92% predicted per month (95% confidence interval, \u22120.53 to 2.37) compared with the retrospective cohort, but this was not statistically significant. Two-year overall survival rates were 76% and 72% for the study participants and the retrospective cohort patients, respectively. Earlier time to diagnosis after hematopoietic cell transplant and severity of FVC at diagnosis were significantly associated with reduced survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The FEV1 trajectory in patients with BOS after hematopoietic cell transplant in a contemporary era of management follows a predominant pattern of rapid FEV1 decline in the 6 months prior to diagnosis, followed by FEV1 stabilization after diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.201604-262oc","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T17:03:28Z","timestamp":1470935008000},"page":"1932-1939","source":"Crossref","is-referenced-by-count":93,"title":["Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4324-9634","authenticated-orcid":false,"given":"Guang-Shing","family":"Cheng","sequence":"first","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"},{"name":"Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Storer","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason W.","family":"Chien","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, Washington"},{"name":"Gilead Sciences, Inc., Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madan","family":"Jagasia","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Vanderbilt University, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J.","family":"Hubbard","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Burns","sequence":"additional","affiliation":[{"name":"National Marrow Donor Program, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Pidala","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Palmer","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic-Scottsdale, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Johnston","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Crothers","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iskra","family":"Pusic","sequence":"additional","affiliation":[{"name":"Division of Medicine and Oncology, Washington University, St. Louis, Missouri; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten M.","family":"Williams","sequence":"additional","affiliation":[{"name":"Children\u2019s Research Institute, Children\u2019s National Health System, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,11,1]]},"reference":[{"key":"2026020502573041200_bib1","first-page":"641","article-title":"Rapidly progressive air-flow obstruction in marrow transplant recipients: possible association between obliterative bronchiolitis and chronic graft-versus-host disease","volume":"129","author":"Ralph","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"2026020502573041200_bib2","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1378\/chest.86.6.824","article-title":"Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation","volume":"86","author":"Burke","year":"1984","journal-title":"Chest"},{"key":"2026020502573041200_bib3","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1056\/NEJMra1204664","article-title":"Obliterative bronchiolitis","volume":"370","author":"Barker","year":"2014","journal-title":"N Engl J Med"},{"key":"2026020502573041200_bib4","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1164\/rccm.200609-1344OC","article-title":"Course of FEV1 after onset of bronchiolitis obliterans syndrome in lung transplant recipients","volume":"175","author":"Lama","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502573041200_bib5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026020502573041200_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbmt.2013.11.025","article-title":"Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease","volume":"20","author":"Palmer","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026020502573041200_bib7","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.bbmt.2015.03.024","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report","volume":"21","author":"Carpenter","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026020502573041200_bib8","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.bbmt.2010.11.018","article-title":"Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation","volume":"17","author":"Au","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026020502573041200_bib9","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"2026020502573041200_bib10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026020502573041200_bib11","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bbmt.2015.10.009","article-title":"Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation","volume":"22","author":"Williams","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026020502573041200_bib12","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026020502573041200_bib13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.2009.1018","article-title":"Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation","volume":"302","author":"Williams","year":"2009","journal-title":"JAMA"},{"key":"2026020502573041200_bib14","first-page":"659","article-title":"Reference spirometric values using techniques and equipment that meet ATS recommendations","volume":"123","author":"Crapo","year":"1981","journal-title":"Am Rev Respir Dis"},{"key":"2026020502573041200_bib15","doi-asserted-by":"crossref","first-page":"368","DOI":"10.7326\/0003-4819-111-5-368","article-title":"Obstructive lung disease after allogeneic marrow transplantation: clinical presentation and course","volume":"111","author":"Clark","year":"1989","journal-title":"Ann Intern Med"},{"key":"2026020502573041200_bib16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/bmt.2012.241","article-title":"Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis","volume":"48","author":"Bergeron","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2026020502573041200_bib17","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/ctr.12638","article-title":"Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Ahn","year":"2015","journal-title":"Clin Transplant"},{"key":"2026020502573041200_bib18","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1164\/rccm.201002-0211OC","article-title":"Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients","volume":"182","author":"Finlen Copeland","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502573041200_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.201501-0174OC","article-title":"Longitudinal forced vital capacity monitoring as a prognostic adjunct after lung transplantation","volume":"192","author":"Belloli","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502573041200_bib20","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.bbmt.2015.01.011","article-title":"Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation","volume":"21","author":"Au","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026020502573041200_bib21","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1164\/rccm.200212-1468OC","article-title":"Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation","volume":"168","author":"Chien","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502573041200_bib22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bbmt.2014.01.008","article-title":"A \u201cwindow of opportunity\u201d for patients with late-onset pulmonary dysfunction after allogeneic hematopoietic cell transplantation","volume":"20","author":"Cooke","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026020502573041200_bib23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1083-8791(03)00242-8","article-title":"Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes","volume":"9","author":"Dudek","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026020502573041200_bib24","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.bbmt.2015.12.023","article-title":"Correlation and agreement of handheld spirometry with laboratory spirometry in allogeneic hematopoietic cell transplant recipients","volume":"22","author":"Cheng","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026020502573041200_bib25","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1164\/rccm.200307-1018OC","article-title":"The predictive value of bronchiolitis obliterans syndrome stage 0-p","volume":"169","author":"Hachem","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502573041200_bib26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1164\/rccm.200501-097OC","article-title":"Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients","volume":"172","author":"Lama","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502573041200_bib27","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.bbmt.2015.02.006","article-title":"Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung","volume":"21","author":"Abedin","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026020502573041200_bib28","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1183\/09031936.05.00035205","article-title":"Interpretative strategies for lung function tests","volume":"26","author":"Pellegrino","year":"2005","journal-title":"Eur Respir J"},{"key":"2026020502573041200_bib29","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.rmed.2013.08.009","article-title":"Small airway impairment in moderate to severe asthmatics without significant proximal airway obstruction","volume":"107","author":"Perez","year":"2013","journal-title":"Respir Med"},{"key":"2026020502573041200_bib30","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1164\/rccm.201410-1818OC","article-title":"Budesonide\/formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation","volume":"191","author":"Bergeron","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502573041200_bib31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/oxfordjournals.aje.a117262","article-title":"Pulmonary function decline and 17-year total mortality: the Honolulu Heart Program","volume":"140","author":"Rodriguez","year":"1994","journal-title":"Am J Epidemiol"},{"key":"2026020502573041200_bib32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/jech.53.4.230","article-title":"Decline in lung function and mortality: the Busselton Health Study","volume":"53","author":"Ryan","year":"1999","journal-title":"J Epidemiol Community Health"},{"key":"2026020502573041200_bib33","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.201412-2269OC","article-title":"Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease","volume":"192","author":"Donaldson","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502573041200_bib34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1164\/rccm.200405-667OC","article-title":"One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis","volume":"171","author":"Ellaffi","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502573041200_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1164\/rccm.201306-1155OC","article-title":"Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction","volume":"189","author":"Todd","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502573041200_bib36","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/bmt.2010.311","article-title":"Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients","volume":"46","author":"Norman","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"2026020502573041200_bib37","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026020502573041200_bib38","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/gerona\/glv201","article-title":"Aging-related considerations when evaluating the forced expiratory volume in 1 second (FEV1) over time","volume":"71","author":"Vaz Fragoso","year":"2016","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2026020502573041200_bib39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1164\/rccm.201106-0992OC","article-title":"Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease","volume":"185","author":"Nishimura","year":"2012","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/13\/11\/1932\/66768568\/annalsats_13_11_1932.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/13\/11\/1932\/66768568\/annalsats_13_11_1932.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:57:45Z","timestamp":1770278265000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/13\/11\/1932\/8449484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,1]]},"published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201604-262oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,11]]},"published":{"date-parts":[[2016,11,1]]}}}